Fig. 5
From: Skeletal muscle-derived cell implantation for the treatment of sphincter-related faecal incontinence
Responder rates according to decrease in weekly incontinence episodes (WIE) over study visits by cause of FI. Patients with FI due to (a) EAS damage (muscle damage, N = 16), (b) EAS atrophy (atrophy, N = 17) and (c) EAS damage and atrophy (both, N = 6). R(100), R(50–99), R(20–49) and R(0–19), percentage of patients (ITT) with decrease in WIE of 100%, 50–99%, 20–49% and 0–19%, respectively from baseline to post-implantation visits. ITT intention to treat, R response, V visit, V2, V3 and V4 1, 6 and 12 months post implantation